A Study of the Zanubrutinib Given in Combination With Bendamustine &

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Active, not recruiting	`NCT03567876` - Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL	Phase 2
Terminated	`NCT02413489` - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma	Phase 2
Not yet recruiting	`NCT04913103` - Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL	Phase 2
Terminated	`NCT00514722` - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies	N/A
Completed	`NCT03682796` - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma	Phase 1
Terminated	`NCT02440685` - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT00420056` - An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.	Phase 1
Completed	`NCT00025662` - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS	Phase 2
Not yet recruiting	`NCT06427213` - This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma	Phase 2
Active, not recruiting	`NCT04849416` - A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)	Phase 2
Completed	`NCT03425591` - A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Completed	`NCT02257242` - Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma	Phase 1
Not yet recruiting	`NCT03910283` - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer	N/A
Completed	`NCT00861510` - A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies	Phase 1
Recruiting	`NCT04735471` - A Phase 1 Study of ADI-001 in B Cell Malignancies	Phase 1
Withdrawn	`NCT05431179` - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma	Phase 3
Completed	`NCT02669017` - Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)	Phase 1
Terminated	`NCT00871546` - SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)	Phase 2
Recruiting	`NCT03647124` - A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT number	NCT06136351
Study type	Interventional
Source	Ruijin Hospital
Contact
Status	Recruiting
Phase	Phase 2
Start date	November 15, 2023
Completion date	November 1, 2027

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms